Prospective study of bacteraemia in cancer patients. Results of a French multicentre study

Supportive Care in Cancer

Volumn 6, Issue 3, 1998, Pages 273-280

  Escande, M C ^a   Herbrecht, R ^b  

^a INSTITUT CURIE   (France)

^b HÔPITAL DE HAUTEPIERRE   (France)

Author keywords

Bacteraemia; Cancer; Epidemiology; In vitro susceptibility testing

Indexed keywords

ADULT; ARTICLE; BACTEREMIA; CANCER; CANCER IMMUNOLOGY; CANCER PATIENT; CANCER RISK; CHILD; HUMAN; INFECTION RISK; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BACTEREMIA; BACTERIA; BACTERIOLOGICAL TECHNIQUES; CEFTAZIDIME; CEPHALOSPORINS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; NEOPLASMS; OPPORTUNISTIC INFECTIONS; PROSPECTIVE STUDIES;

EID: 0031948504     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005200050166     Document Type: Article

References (30)

1. Andremont A, Lancar R, Ngoc AL, Hattchouel JM, Baron S, Tavakoli T, Daniel MF, Tancrede C, Le MG (1996) Secular trends in mortality associated with bloodstream infections in 4268 patients hospitalized in a cancer referral center between 1975 and 1989. Clin Microbiol Infect 1:160-167
2. Archer GL, Climo MW (1994) Anti-microbial susceptibility of coagulase-negative staphylococci. Antimicrob Agents Chemother 38:2231-2237
3. Awada A, Van der Auwera P, Meunier F, Daneau D, Klastersky J (1992) Streptococcal bacteremia in cancer patients. Clin Infect Dis 15:33-48
4. Bochud PY, Calandra T, Francioli P (1994) Bacteremia due to viridans streptococci in neutropenic patients: a review. Am J Med 97:256-264
5. Bodey GP (1986) Infection in cancer patients. A continuing association. Am J Med 81 [Suppl 1A]:11-26
6. Bodey GP, Jadeja L, Elting L (1985) Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch Intern Med 145:1621-1629
7. Carlisle PS, Gucalp R, Wiernik PH (1993) Nosocomial infections in neutropenic cancer patients. Infect Control Hosp Epidemiol 14:320-324
8. Chanock S (1993) Evolving risk factors for infectious complications of cancer therapy. Hematol Oncol Clin North Am 7:771-793
9. Comité de l'Antibiogramme de la Société Française de Microbiology (1994) Comuniqué. Pathol Biol (Paris) 42:1-8
10. Coullioud D, Combe F, Latour JF, Chauvin F, Bigot P (1990) Incidence of nosocomial infections in anticancer centre. clinical and bacteriological data. Bull Cancer 77:893-900
11. Coullioud D, Van der Auwera P, Viot M, Lasset C, CEMIC (1993) Prospective multicentric study of the etiology of 1051 bacteremic episodes in 782 cancer patients. Support Care Cancer 1:34-46
12. Doern GV, Ferraro MJ, Brueggemann AB, Ruoff KL (1996) Emergence of high rates of anti-microbial resistance among viridans group streptococci in the united states. Antimicrob Agents Chemother 4:891-894
13. Durand-Gasselin B, Leclercq R, Girard-Pipau F, Deharvengt MC, Rochant H, Astier A, Duval J, Cordonnier C (1995) Evolution of bacterial susceptibility to antibiotics during a six-year period in a haematology unit. J Hosp Infect 29:19-33
14. Eggimann P (1995) Special feature in the handling of infections in neutropenic patients. Med Hyg 53:1073-1081
15. EORTC International Anti-microbial Therapy Cooperative Group (1990) Gram positive bacteraemia in granulocytopenic cancer patients. Eur J Cancer 26:569-574
16. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM (1988) CDC definitions for nosocomial infections. Am J Infect Control 16:128-140
17. Gerson SL, Talbot GH, Hurwitz S, Strom BL, Lusk EJ, Cassileth PA (1984) Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med 100:345-351
18. Herbrecht R (1994) Gram positive cocci infections in cancer patients. Med Mal Infect 24:1222-1228
19. Jarlier V, Nocolas MH, Fournier G, Philipon A (1988) Extended broad-spectrum betalactamases conferring transferable resistance to newer betalactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev Infect Dis 10:867-878
20. Klastersky J, Zinner SH, Calandra T, Gaya H, Glauser MP, Meunier F, Rossi M, Schimpff SC, Tattersall M, Viscoli C, EORTC Anti-microbial Therapy Cooperative Group (1988) Empiric anti-microbial therapy for febrile granulocytopenic cancer patients: lessons from four EORTC trials. Eur J Cancer Clin Oncol 24 [Suppl 1]: S35-S45
21. Lowder JN, Lazarus HM, Herzig RH (1982) Bacteremias and fungernias in oncologic patients with central venous catheters. Changing spectrum of infection. Arch Intern Med 130:1456-1459
22. MacGregor RR, Beaty HN (1972) Evaluation of positive blood cultures. Guidelines for early differentiation of contamined from valid positive cultures. Arch Intern Med 130:84-87
23. Potgieter E, Carmichael M, Koornhof HJ, Chalkley LJ (1992) In vitro anti-microbial susceptibility of viridans streptococci isolated from blood cultures. Eur J Clin Microbiol Infect Dis 11:543-546
24. Reeves DS, Bywater MJ, Holt HA (1993) The activity of cefpirome and ten other antibacterial agents against 2858 clinical isolates collected from 20 centres. J Antimicrob Chemother 31:345-362
25. Rostein C, Cummings KM, Nicolaou AL, Lucey J, Fitzpatrick J (1988) Nosocomial infection rates at an oncology center. Infect Control Hosp Epidemiol 9:13-19
26. Sanders CC, Sanders WE (1985) Microbial resistance to newer β-lactam antibiotics: clinical and laboratory implications. J Infect Dis 151:399-406
27. Sirot DL, Goldstein FW, Soussy CJ, et al (1992) Resistance to cefotaxime and seven other betalactams in members of the family Enterobacteriaceae : a 3-year survey in France. Antimicrob Agents Chemother 36:1677-1681
28. Viscoli C, Perlino G, De Bernardi B, et al (1985) Infections in children with cancer. Riv Ital Pediatr 11:37-43
29. Voss A, Milatovic D, Wallrauch-Schwarz C, Rosdahl VT, Braveny I (1994) Methicillin-resistant Staphylococcus aureus in Europe. Eur J Clin Microbiol Infect Dis 13:50-55
30. Winston DJ, Dudnick DV, Chapin M, Ho WG, Sale RP, Martin MJ (1983) Coagulase-negative staphylococcal bacteraemia in patients receiving immunosuppressive therapy. Arch Intern Med 143:32-36